Processing .....please wait.. 
The article has been forwarded.... 
Biocon for U.S. expansion
By Sources
|
Thursday, 07 July 2005, 19:30 IST
BANGALORE: Biotech major Biocon is in the process of registering Insugen, its branded formulation of recombinant human insulin, in over 25 countries.
It is also preparing for the early entry of generic versions of Simvastatin and Pravastatins in U.S.
The company is finalizing marketing arrangements for insulin across the world. The European regulatory authorities have recently inspected its insulin facility as a first step towards preparing for a market entry in Europe, said Kiran Mazumdar Shaw.
The company's cardio-diabetes drugs have also made steady progress in the Indian market and the company is expected to substantially build on this initial success in the year ahead.
According to her, immuno-suppressants, another growth driver, offers significant opportunities given the high entry barriers that exist in this segment.
We have entered into several marketing arrangements with a number of global pharmaceutical companies who anticipate market entry between 2007 to 2009, for a range of immuno-suppressants, she said.
Speaking about statins, Kiran Mazumdar Shaw said that they were the growth drivers in the last fiscal. It garnered an increased market share both in Europe and US while experiencing strong pricing pressure in the European markets.
The year is likely to see a surge in statin sales to the US markets. in Q4 of FY 05. The company has begun preparation for the entry of generic Simvastatin and Pravastatin in mid 2006. The company has also made substantial progress on its major expansion project which is expected to be fully operational by Q2 this fiscal," she added.